section name header

Pronunciation

o-ma-LIZ-ue-mab

Classifications

Therapeutic Classification: antiasthmatics

Pharmacologic Classification: monoclonal antibodies

Indications

REMS


Action

  • Inhibits binding of IgE to receptors on mast cells and eosinophils, preventing the release of mediators of the allergic response. Also lowers amount of IgE and decreases amount of IgE receptors on basophils.
Therapeutic effects:
  • Decreased incidence of exacerbations of asthma.
  • Decreased severity of itching and quantity of hives.
  • Reduction of Type I allergic reactions, including anaphylaxis.
  • Decreased size of nasal polyps and decreased severity of nasal congestion.

Pharmacokinetics

Absorption: 62% absorbed slowly from SUBQ sites.

Distribution: Unknown.

Metabolism/Excretion: Degraded similarly to IgG via binding degradation, reticuloendothelial system and the liver.

Half-Life: 26 days.

Time/Action Profile

(effects on IgE levels)

ROUTEONSETPEAKDURATION
SUBQwithin 1 hrunknownup to 1 yr

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Interactions

Drug-drug:

Route/Dosage

Asthma

Chronic Idiopathic Urticaria

IgE-Mediated Food Allergy

Chronic Rhinosinusitis with Nasal Polyps

Availability

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Xolair

Code

NDC Code